Heartflow, Inc.

HTFL

Held by 3 specialist biotech funds

High Convergence

Share on X

Fund Holdings

3 fund convergence

Rock Springs Capital RTW Investments Eventide Asset Management

Position Trend

Feb 13, 2026

$14.8M

1 fund

Feb 17, 2026

$22.5M

2 funds

+53% total institutional value over 2 quarters

Catalysts

No catalysts tracked.

Position Details

Rock Springs CapitalNEWFeb 17, 2026

Shares: 277,700Value: $8.1M

# Signal Note: Rock Springs Capital Initiates HeartFlow Position Rock Springs' $8.1M entry into HTFL (277.7K shares, ~2.8% of portfolio at typical concentrated fund sizing) signals conviction in the company's AI-driven coronary artery disease diagnostic platform as it faces near-term clinical/commercial inflection points. The initiation likely reflects confidence in HTFL's FFR-CT technology's reimbursement trajectory and competitive positioning versus invasive catheterization, though the timing warrants monitoring for upcoming data releases, payer coverage decisions, or partnership announcements that could justify a healthcare specialist's concentrated bet.

RTW InvestmentsNEW

More HTFL Analysis

Insider buy/sell details with names, titles, and amounts
AI-generated context for every signal

Start 7-Day Free Trial — $29/mo

Insider Signals

No insider signals tracked.

Also Held by These Funds

ISRG3 funds CYTK3 funds INSM3 funds ARGX3 funds KYMR3 funds NBIX2 funds OLMA2 funds AMLX

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Track specialist biotech funds, insider signals, and AI analysis

Start 7-Day Free Trial

Or get the free weekly brief:

AI Signal

AI analyst context — unlock full analysis

# Signal Note: RTW Investments Initiates HTFL Position **Key takeaway:** RTW's $14.4M entry into HeartFlow signals conviction in the company's AI-driven coronary angiography platform and recent FDA clearances expanding non-invasive cardiac imaging adoption. The position timing likely reflects confidence in upcoming adoption metrics and potential reimbursement expansion, as HeartFlow captures share from invasive catheterization procedures in stable CAD diagnosis.